Evidence map›Paper›PMID 38806758›Full record

ReviewCalcified tissue international2024

A Rare Association Between Osteomalacia, Phosphaturic Mesenchymal Tumor, and Ovarian Cancer: A Case Report and Literature Review.

Marcodomenico Mazza, Gaetano Paride Arcidiacono, Ilda Hoxhaj, Virginia Padoan, Giulia Tasca, Marta Burei, Stefania Sella, Paolo Simioni, Sandro Giannini, Simone Mocellin

Abstract readCase ReportsReview
In one paragraph

Review in Calcified tissue international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marcodomenico Mazza *Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Gaetano Paride Arcidiacono *Department of Medicine, Clinica Medica 1, University of Padova, Via Giustiniani 2, Padua, Italy. gaetano.arcidiacono@unipd.it.ORCID 0000-0003-0409-4449
Ilda HoxhajDepartment of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padova, Padua, Italy.
Virginia PadoanDepartment of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padova, Padua, Italy.
Giulia TascaOncology 2 Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Marta BureiNuclear Medicine Unit, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy.
Stefania SellaDepartment of Medicine, Clinica Medica 1, University of Padova, Via Giustiniani 2, Padua, Italy.
Paolo SimioniDepartment of Medicine, Clinica Medica 1, University of Padova, Via Giustiniani 2, Padua, Italy.
Sandro GianniniDepartment of Medicine, Clinica Medica 1, University of Padova, Via Giustiniani 2, Padua, Italy.
Simone MocellinDepartment of Surgical, Oncological and Gastroenterological Sciences (DISCOG), University of Padova, Padua, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome characterized by hypophosphatemia, bone mineralization disorders with increased risk of fragility fractures, muscle pain, and progressive weakness. TIO has been associated with increased production of the phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) usually by mesenchymal tumors of soft tissue or bone (Phosphaturic Mesenchymal Tumors-PMTs). In rare cases TIO may be observed in association with other malignancies. We report the case of a 66-year-old woman with an occasional diagnosis of both a PMT and an ovarian cancer during the evaluation of TIO. We also systematically review the literature to discover possible correlations between osteomalacia, FGF23 production, and ovarian cancer. Four studies were eligible for the analysis. Two case reports described an association between TIO development and ovarian cancer, whereas the two case-control studies hypothesized a possible correlation between FGF/FGF receptor axis and cancer development. Although it does not provide conclusive evidence regarding the association between TIO and ovarian cancer, this case report highlights the possibility that in the diagnostic workup of suspected TIO, both FGF23-secreting tumors distinct from PMT and tumors unrelated to the clinical presentation of TIO could be identified. This information is important for guiding successful tumor staging and determining the necessity for surgical intervention and/or eventual adjuvant therapy.

Indexed as

Fibroblast Growth Factor-23Fibroblast Growth FactorsOsteomalaciaOvarian NeoplasmsParaneoplastic SyndromesAgedFemaleHumansHypophosphatemiaNeoplasms, Connective TissueFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsFGF23Ovarian cancerPhosphaturic mesenchymal tumorTumor-induced osteomalacia

Identifiers

PMID38806758
PMCPMC11246267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.